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Abstract
Squamous cell carcinoma (SCC) of the skin is a malignancy arising from epithelial keratinocytes. Experimental and epidemiologic evidence raise the possibility
that human polyomaviruses (PyV) may be associated with the occurrence of
SCC. To investigate whether the risk for SCC was associated with PyV infection,
seropositivity to 10 PyV types was assessed following diagnosis in a population-
based case–control study conducted in the United States. A total of 253 SCC
cases and 460 age group and gender-matched controls were included. Antibody
response against each PyV was measured using a multiplex serology-based glutathione S-
transferase capture assay of recombinantly expressed VP1 capsid
proteins. Odds ratios (OR) for SCC associated with seropositivity to each PyV
type were estimated using logistic regression, with adjustment for potentially
confounding factors. SCC cases were seropositive for a greater number of PyVs
than controls (P = 0.049). Those who were JC seropositive had increased odds
of SCC when compared to those who were JC seronegative (OR = 1.37, 95%
CI: 0.98–1.90), with an increasing trend in SCC risk with increasing quartiles
of seroreactivity (P for trend = 0.04). There were no clear associations between
SCC risk and serostatus for other PyV types. This study provides limited evidence that infection with certain PyVs may be related to the occurrence of SCC
in the general population of the United States.

doi: 10.1002/cam4.674

Introduction
Cutaneous squamous cell carcinoma (SCC) is a keratinocyte cancer (KC), with increasing incidence rates reported
in the United States [1–4], Australia [5, 6], and Europe
[7, 8]. Estimates of up to 420,000 individuals in the United
States were diagnosed with incident SCC in 2012, and
8800 SCC patients died from this malignancy [2].
Established risk factors include elderly age [1, 4, 9] and
ultraviolet light [10, 11], but environmental exposure to
ionizing radiation [12, 13], arsenic [14–17], and polycyclic
aromatic hydrocarbons [18, 19] further increases the risk

of SCC. Inherited traits such as skin pigmentation [20,
21] and genetic defects in the ability to correct DNA
photolesions (e.g., xeroderma pigmentosum) [22–24] also
contribute to risk. While the prognosis is generally favorable, metastases can occur; and the aging population, as
well as disfigurement and morbidity resulting from SCC,
makes this malignancy an important public health concern
and under-recognized health burden.
Immunocompromised persons (e.g., organ transplant
recipients, and those given immunosuppressant medications) carry a higher risk of SCC [1, 4, 25–28], raising
the possibility of a viral etiology. However, the detection

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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of viral sequences in tumors can reflect either a causal
or bystander role [29, 30]. Thus far, genus β human
papillomaviruses (HPV) [31, 32] have been associated with
an increased risk of SCC, but a causal relationship has
not yet been established in the general population [33].
A potential etiologic role for polyomaviruses (PyV) in
cancer has been investigated, and a rapidly expanding
number of viral types are being identified in the family
Polyomaviridae (reviewed in DeCaprio & Garcea, 2013
[34]). PyVs are DNA viruses with an icosahedral capsid
~45 nm in diameter containing a circular double-stranded
genome [35, 36] that encodes capsid proteins (VP1, VP2,
and VP3), as well as small and large T antigens (TAg)
[35]. In simian virus-40 (SV40), a PyV naturally infecting
Asian macaques [37, 38], the large TAg possesses tumorigenic properties, including the ability to bind and thereby
inactivate tumor suppressor proteins Rb [39] and p53,
[40] stimulating host cell cycle [35].
While the ability of PyVs to cause tumors in vitro and
in experimental systems is undisputed, their role in human
malignancies—and specifically KCs—is just beginning to
emerge. Multiple human PyVs show evidence of skin tropism,
including Merkel cell polyomavirus (MCV), Trichodysplasia
spinulosa–associated polyomavirus (TSV), and human polyomaviruses 6 and 7 (HPyV6 and HPyV7) [36]. MCV was
initially discovered in Merkel cell carcinoma (MCC) of the
skin [41], and integration of the viral genome in MCC
tumors [42] with potentially carcinogenic mutations in the
large TAg [43] supported a causal role for MCV in MCC
development. Recently, a clinic-based case–control study from
Florida, USA, found an increased SCC risk associated with
antibodies against MCV measured following diagnosis, and
the association was stronger among those with tumors containing MCV viral sequences [44]. Conversely, a case–control
study conducted within organ transplant recipients found
no evidence of an association between SCC development
following transplant surgery and the seroprevalence of numerous PyV types prior to transplantation [45]. Further, a large
prospective Swedish study found no association between SCC
and JC seropositivity assessed prior to diagnosis [46].
Limited epidemiologic research exists on the role of
PyV infections (apart from MCV) in SCC carcinogenesis.
We therefore sought to investigate the potential association between PyVs and SCC by performing a comprehensive serologic analysis of the frequency of antibodies
to the first 10 identified human PyVs: BK virus [47]; JC
virus [48]; Karolinska Institute polyomavirus (KI) [49];
Washington University polyomavirus (WU) [50]; MCV
[41]; HPyV6 and HPyV7 [51]; TSV [52]; human polyomavirus 9 (HPyV9) [53]; and Malawi/human polyomavirus 10 (HPyV10) [54] in plasma samples collected as
part of a large, population-based case–control study conducted in New Hampshire, USA.
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Materials and Methods
Study population
The New Hampshire Skin Cancer Study population and
methods have been described in detail elsewhere (epidemiologic study design described in Karagas et al., 1998
[55]) [32, 56, 57]. Briefly, histologically-confirmed, incident
SCC cases were identified through active surveillance of
dermatology and pathology laboratories throughout New
Hampshire, USA. We selected all identified SCC cases
diagnosed between July 1993 and June 1995, during the
first enrollment phase of this large, population-
based
case–control study. Controls were selected from lists of
New Hampshire residents obtained from the New
Hampshire Department of Transportation (<65 years) and
Medicare enrollment lists (≥65 years), and frequencymatched to the age (25–34, 35–44, 45–54, 55–64, 65–69,
and 70–74 years) and gender distribution of cases. For
the purpose of the interview, controls were randomly
assigned a reference date that matched a case’s diagnosis
date. To be eligible, participants were required to be residents of New Hampshire, aged 25–74 years at time of
diagnosis, speak English, and have a listed telephone
number. We excluded participants with squamous cell or
basal cell carcinomas on genital sites.
Study participants completed an extensive, structured
interview, usually in their homes. Personal interviews were
conducted to obtain sociodemographic information (e.g.,
level of education), lifestyle factors (e.g., cigarette smoking), sunlight-related characteristics (e.g., response to first
exposure in summer to 1 h of sunlight, number of severe
sunburns, and skin color), and medical history (e.g., prior
history of skin cancer, use of oral glucocorticoids for
1 month or longer, and organ transplant status). Data
on the primary tumor(s) (e.g., SCC anatomical location)
were collected from a medical records review. Tumors
diagnosed as a recurrence of a previously treated tumor,
and those appearing contiguous with a scar from a previously excised skin cancer, were not considered a new
primary SCC and thus were excluded. All participants
provided informed consent in accordance with the
Committee for the Protection of Human Subjects at
Dartmouth College.

Human polyomavirus serology
As part of the New Hampshire Skin Cancer Study, we
requested a blood sample from all participants for use
in future research [55]. We collected venous blood samples
of 20–30 mL in heparinized tubes following SCC diagnosis
(as described in [32, 56]). Blood was separated by centrifugation at 2500g for 20 min at 4°C, and each

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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component (plasma, red blood cells, and buffy coat) was
labeled and stored separately at −80°C until analysis.
Specimen label did not reveal the case–control status of
the study participant. Samples were shipped to the German
Cancer Research Center (DKFZ; Heidelberg, Germany)
on dry ice for analysis.
Plasma samples were assayed for antibodies against the
immunodominant VP1 capsid protein [58] of 10 human
PyVs (BK, JC, KI, WU, MCV isolate 344, HPyV6, HPyV7,
TSV, HPyV9, and HPyV10). Plasma samples were also
tested for antibodies against the TAg of selected PyV types
(large TAg for BK, JC, MCV, HPyV6, HPyV7, TSV,
HPyV10, and small TAg for MCV). In our prior study,
we did not find strong positive correlations or evidence
of cross-reactivity between the VP1 capsid proteins of
most PyV types (data not shown), suggesting that risk
estimates obtained during analysis would be specific to
that PyV type [59]. However, the strong positive correlations between TAg seroreactivities from various PyVs
suggestive of assay cross-reactivity (Fig. S1), and the small
number of participants TAg seropositive, resulted in the
exclusion of TAg serostatus from the presented analyses.
The multiplex antibody detection approach was based on
a glutathione S-transferase (GST) capture enzyme-linked
immunosorbent assay (ELISA) method in combination
with fluorescent bead technology (Luminex Corp., Austin,
Texas) [60, 61]. Antigen preparation and techniques used
for PyVs [44, 58, 62] closely follow methods applied to
HPVs as described previously [60, 63].
Seroreactivity against PyV VP1 proteins was expressed
as the median fluorescence intensity (MFI) of 100+ beads
of the same internal color [61]. MFI values reflect antibody affinity, titer, and reactivity determined by dilution
series [64]. Standard cut points to define seropositivity
were chosen for each PyV by visual inspection of frequency
distribution curves (percentile plots) for the inflection
points of all sera tested, as done in prior studies [56, 62,
63, 65]. The standard cutoff value for VP1 was 250 MFI
units for all 10 PyVs (as used in Teras et al., 2014 [66]
and Gossai et al., 2016 [59]). To evaluate the robustness
of odds ratio (OR) estimates for SCC by PyV seropositivity, we used a sliding cut point between 50 and 450 MFI
units, and also calculated cut points from controls using
a method adapted from van der Meijden et al., 2013 [67]
(Fig. S2). Given the stability of ORs to cut point definition, we ultimately used the standard cut points in all
analyses.

Statistical analysis
Individual characteristics of SCC cases and controls were
compared using the X2 test (for categorical variables, i.e.,
gender, education, smoking status, skin color, skin sun

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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sensitivity, number of sunburns, prior KC, glucocorticoid
use) or Fisher’s exact test (for categorical variables with
small strata, i.e., transplant recipients), and Wilcoxon rank
sum test (for continuous variables, i.e., age, mean number
of PyVs seropositive). Among controls, we previously
published the seroprevalence of each PyV type, and tested
the association between various individual characteristics
in relation to PyV seropositivity; therefore, these analyses
were not repeated in this study [59].
We used unconditional logistic regression to calculate
the ORs and 95% confidence intervals (CI) for SCC by
VP1 seropositivity compared to seronegativity for each
PyV type, while adjusting for age group and gender (as
used in the frequency matching). We also examined seropositivity for multiple PyV types (7–8 and 9–10 types
positive compared with 1–6 types positive), and calculated
a P for trend based on these categories and a continuous
variable of the number of types seropositive. Quartiles of
seroreactivity based on the control distributions of continuous MFI values were created for each PyV, and associated with SCC by comparing the second, third, and
fourth quartile to the first (lowest) quartile. Tests for
trend were conducted by including an ordinal variable
in the logistic model. In addition, we evaluated seropositivity for multiple cutaneous PyVs (i.e., MCV, HPyV6,
HPyV7, and TSV), and whether seropositivity for all 4
or ≤3 cutaneous PyVs, was associated with SCC risk.
Potentially confounding covariates included level of
education, smoking status, eye color, hair color, skin color,
skin sensitivity to the sun, number of lifetime painful
sunburns, lifetime sun exposure, and the self-reported use
of oral glucocorticoids for 1 month or longer. As none
of these factors consistently produced a >10% change in
OR [68] when individually placed in a logistic regression
model including the frequency matching factors (age group
and gender), our OR estimates were ultimately adjusted
for only these factors.
We assessed the potential modifying effects of prolonged
oral glucocorticoid use for reasons other than organ transplantation, as PyVs have been related to skin conditions
and cancers in immunosuppressed populations. In these
stratified analyses, we classified participants as users if
they reported taking glucocorticoids for 1 month or longer,
and excluded those who reported having had an organ
transplant. An association between SCC risk and seropositivity to multiple cutaneous β HPVs has been reported
previously [31, 32]. Therefore, using published serologic
data from the New Hampshire Skin Cancer Study [31,
32] on 16 cutaneous β HPVs (specifically, 5, 8, 20, 24,
36 (beta-
1); 9, 15, 17, 23, 38, 107 (beta-
2); 49, 75, 76
(beta-3); 92 (beta-4); and 96 (beta-5)), we stratified participants by those with seropositivity to 0–1 or seropositivity
to ≥2 β HPV types to assess possible effect modification
1241
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by concomitant β HPV infections. We further calculated
separate ORs for SCC occurring exclusively on anatomical
sites with chronic sunlight exposure (head or neck) and
other body sites in comparison to controls.
As sensitivity analyses, we excluded participants with a
history of organ transplantation (n = 7), restricted to
participants with no previous skin cancers (neither a prior
SCC nor BCC; n = 423 controls and 179 cases), and
excluded participants with a concomitant basal cell carcinoma (n = 22 cases) to assess whether the OR estimates
differed from those obtained for all participants. No
appreciable change in results was detected (Fig. S3), and
thus these individuals were included in the presented
analyses. All statistical tests were two-sided and significance
was assessed at the α = 0.05 level. Statistical analyses
were performed in R version 3.0.1.

Results
Study population characteristics
Plasma samples for PyV serology were obtained from 253
(86.3%) of the 293 interviewed SCC cases following diagnosis, and 460 (85.2%) of the 540 interviewed controls
(excluding 1 control with an insufficient bead count during
serologic analysis). No appreciable differences were noted
in the characteristics of individuals for whom we did not
obtain serology data (data not shown). Compared to
controls, SCC cases were older, were of lighter skin color,
had skin that tended to burn following sun exposure,
reported a greater number of painful sunburns in their
lifetime, were more likely to have had a prior KC (SCC
and/or BCC), and were more likely to have had an organ
transplant (Table 1).

Polyomaviruses and cutaneous squamous
cell carcinoma
Seroprevalences ranged from 17.6% for HPyV9 to 99.1%
for HPyV10 among controls, and from 22.9% for HPyV9
to 98.8% for HPyV10 among cases (Fig. 1). All study
participants were seropositive for at least one type of PyV,
but cases (mean = 7.52, standard deviation = 1.40) were
seropositive for a slightly greater number of PyVs than
controls (mean = 7.30, standard deviation = 1.45; Wilcoxon
rank sum test P = 0.049). However, we found no evidence
of an increasing trend in SCC odds with increasing number
of PyV types for which an individual tested seropositive,
either using a categorical variable (P for trend = 0.42)
or on a continuous scale (P = 0.32) (Table 2). Further,
no association with SCC was observed for combined seropositivity to the known cutaneous PyVs (i.e., MCV, HPyV6,
HPyV7, and TSV; Table S2).
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Table 1. Selected characteristics of cutaneous squamous cell carcinoma
(SCC) cases and controls from the New Hampshire Skin Cancer Study
(n = 713).1
Variable

SCC cases (n = 253),
No. (%)

Gender
Male
168 (66.4)
Female
85 (33.6)
Median age, SD (years)
68 (8.0)
Education
Elementary to high or
111 (43.9)
technical school
Any college
80 (31.6)
Graduate or professional
61 (24.1)
school
Smoking status2
Never
79 (31.2)
Former
133 (52.6)
Current
40 (15.8)
Skin color
Light
213 (84.2)
Medium
38 (15.0)
Skin sun sensitivity3
Severe sunburn with
22 (8.7)
blistering
Painful sunburn and
93 (36.8)
then peeling
Mild sunburn with some
111 (43.9)
tanning
Tan without sunburn
25 (9.9)
No. of lifetime painful sunburns4
0
66 (26.1)
1–2
49 (19.4)
3+
136 (53.8)
Prior keratinocyte cancer5
Yes
74 (29.2)
No
179 (70.8)
Glucocorticoid use6
Yes
33 (13.0)
No
211 (83.4)
Transplant recipient
Yes
6 (2.4)
No
246 (97.2)

Controls (n = 460),
No. (%)
280 (60.9)
180 (39.1)
65 (10.7)***
227 (49.3)
144 (31.1)
89 (19.3)

146 (31.7)
230 (50.0)
84 (18.3)
279 (60.6)***
180 (39.1)
28 (6.1)***
116 (25.2)
234 (50.9)
80 (17.4)
147 (32.0)***
134 (29.1)
174 (37.8)
37 (8.0)***
423 (91.9)
39 (8.5)
415 (90.2)
1 (0.2)**
458 (88.6)

*P < 0.05, **P < 0.01, ***P < 0.001. P values obtained from X2, Fisher’s
exact, or Wilcoxon rank sum test (as appropriate) comparing sociodemographic and skin cancer risk factors between SCC cases and
controls.
1Numbers may not sum to the overall total due to missing data. They
were excluded from complete case analyses.
2Cigarette smoking status at 1 year prior to the reference or diagnosis
date
3Sun sensitivity was defined as the skin reaction to 1 h of sun exposure
the first time in the summer.
4Sunburns that caused pain for 2 or more days
5Prior keratinocyte cancer was defined as having had a previous squamous cell, basal cell, or both squamous cell and basal cell carcinoma.
6Glucocorticoid use was defined as having used oral steroid or corticosteroid medications (e.g., cortisone or prednisone) for 1 month or longer.

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Figure 1. Odds ratios (95% confidence intervals as whiskers) for cutaneous squamous cell carcinoma (SCC) by seropositivity for each polyomavirus
(PyV) type among 713 study participants from the New Hampshire Skin Cancer Study. The overall seroprevalences (%) and number of participants
who were seropositive for each PyV are shown below the plot area separately for cases and controls.
Table 2. Odds ratios (95% confidence intervals) for cutaneous squamous cell carcinoma (SCC) by number of polyomavirus (PyV) types seropositive among 713 study participants from the New Hampshire Skin
Cancer Study.

Table 3. Odds ratios (95% confidence intervals) for cutaneous squamous cell carcinoma (SCC) by quartiles of JC polyomavirus (PyV) seroreactivity among 713 study participants from the New Hampshire Skin
Cancer Study.

No. of PyV types
seropositive

OR (95% CI)1

PyV seroreactivity Controls (n = 460), SCC cases (n = 253)
(MFI units)
No. (%)
No. (%)
OR (95% CI)1

1.00 (referent)
1.04 (0.71–1.53)
1.21 (0.76–1.91)
0.42
1.06 (0.95–1.18)

JC
Quartile 1
Quartile 2
Quartile 3
Quartile 4
P for trend

Controls
(n = 460),
No. (%)

1–6
129 (28.0)
7–8
236 (51.3)
9–10
95 (20.6)
P for trend
Continuous
7.30 (1.45)
[mean No. (SD)]
P

SCC cases (n = 253)
No. (%)
60 (23.7)
128 (50.6)
65 (25.7)
7.52 (1.40)

0.32

OR, odds ratio; CI, confidence interval; SD, standard deviation.
for age group and gender.

115 (25.0)
115 (25.0)
115 (25.0)
115 (25.0)

51 (20.2)
43 (17.0)
74 (29.2)
85 (33.6)

1.00 (referent)
0.79 (0.48–1.30)
1.27 (0.80–1.99)
1.41 (0.90–2.20)
0.04

OR, odds ratio; CI, confidence interval.
for age group and gender.

1Adjusted

1Adjusted

In an analysis of SCC associations with antibodies to
specific capsid antigens from each PyV type (classified as
a dichotomous variable), an elevated odds of SCC was
observed with seropositivity to JC of borderline statistical
significance (OR = 1.37, 95% CI: 0.98–1.90; Fig. 1), and
a positive trend in SCC risk was associated with increasing MFI quartiles of JC seroreactivity (P for trend = 0.04)
(Table 3). A weakly positive association with SCC risk

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

was observed for seropositivity to WU (OR = 2.04, 95%
CI: 0.64–6.49) (Fig. 1), and a slightly inverse association
with SCC risk was observed for seropositivity to HPyV10
(OR = 0.72, 95% CI: 0.16–3.32), but neither estimates
achieved statistical significance. There were no trends in
SCC risk by MFI quartiles for any PyV type but JC (Table
S1).
SCC was more strongly related with seropositivity to
JC among those reporting oral glucocorticoid use for
1243
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1 month or longer (OR = 1.88, 95% CI: 0.61–5.76) than
those without a history of prolonged glucocorticoid use
(OR = 1.37, 95% CI: 0.96–1.96)—albeit with limited statistical power (P for interaction = 0.50; Fig. S4). When
excluding glucocorticoid users, the positive association
between SCC risk and HPyV9 seropositivity was strengthened (OR = 1.49, 95% CI: 0.99–2.24). Interestingly, a
weakly positive association with SCC risk was found for
HPyV10 seropositivity among those seropositive for <2
β HPV types (OR = 1.45, 95% CI: 0.15–14.37), although
with wide confidence intervals. We did not find any notable
differences for the other PyVs according to glucocorticoid
use, anatomical site of the SCC tumor, or seropositivity
to β HPVs, in stratified analyses.

Discussion
We measured antibodies against the first 10 discovered
human PyVs in a large, population-
based case–control
study to investigate the relation between multiple PyVs
and SCC incidence. No clear associations were observed
for most PyV types and SCC risk. However, we observed
an intriguing elevated odds ratio for SCC associated with
JC seropositivity that approached statistical significance,
and a trend in risk by quartiles of JC seroreactivity. While
no clear associations were detected, we had limited statistical power for many of these analyses due to the high
PyV seroprevalence.
Several epidemiologic studies have raised the possibility
of an oncogenic role for PyV infection in SCC development. Among 173 SCC cases and 300 controls in a clinic-
based case–control study conducted in Florida, USA, MCV
seropositivity was related to an increased risk for SCC
(OR = 1.58, 95% CI: 0.96–2.60), and the association was
strongest among those with tumors containing MCV DNA
(OR = 2.49, 95% CI: 1.03–6.04) [44]. We did not observe
evidence of an association with MCV seropositivity. An
association of a similar magnitude with JC seropositivity
was also observed in the Florida study (OR = 1.40, 95%
CI: 0.89–2.20). However, unlike our study, there was no
trend by quartiles of JC seroreactivity (P for trend = 0.44)
[44].
In our case–control study design, we are unable to
address the issue of ‘reverse causality’ common to studies
aiming to elucidate the etiology of KC at or following
diagnosis. Namely, it is possible that antibodies measured
at the time of SCC diagnosis do not accurately reflect
antibodies that would have been circulating in the early
stages of carcinogenesis. Indeed, a large, prospective,
Swedish study which drew upon samples donated to a
biobank and cancer registry data found no association
between SCC (OR = 1.0, 95% CI: 0.8–1.4) or BCC
(OR = 0.9, 95% CI: 0.8–1.1) and prediagnostic JC
1244
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seropositivity, with blood samples collected at least 1 month
prior to diagnosis [46]. However, the primary hypothesis
of the Swedish study was an association between HPV
and SCC or BCC, and thus used a multiplex assay optimized for the detection of antibodies against various HPV
types, with JC included as a specificity control [46]. A
discrepancy in results may be attributed to both differing
populations and assay optimization for human PyV types.
Thus, further prospective data that include repeated measurements over time from each participant are needed.
Increased incidence of cancers in immunosuppressed
patients, such as skin cancers [27], suggests a possible
viral etiology that may be attributed to impaired immune
surveillance of infections with oncogenic potential.
Moreover, immune suppression could lead to viral reactivation and higher levels of antibodies, thus confounding
any observed relationship between PyVs and SCC. A greater
than expected proportion of transplant recipients are seropositive for KI and WU [69, 70], and MCV sequences
are also more frequently found in the skin tumors of
immunocompromised patients than those from immunocompetent individuals [71]. TSV seroprevalence is likewise
higher in renal transplant patients when compared to
healthy participants [72], and has been causally linked to
a rare disease of abnormal maturation of the hair follicles
characterized by spiny lesions on the skin [73, 74]. HPyV9
was first isolated from a kidney transplant recipient [53]
and has been found at higher seroprevalence in immunocompromised patients [75]. HPyV10 was isolated from
a patient with warts, hypogammaglobulinemia, infections,
and myelokathexis (WHIM) syndrome [54], an inherited
immune deficiency with increased susceptibility to HPV-
induced warts and cancers [76, 77]. BK and JC are known
to reactivate under conditions of immunosuppression [78,
79]. Indeed, JC seropositivity has been used as an indicator
of immune status in prior studies [44]. In a small, nested
case–control study among transplant recipients, no excess
risks for SCC following organ transplantation were found
with antibody levels against PyVs (specifically, JC, KI, WU,
MCV, HPyV6, and HPyV7) in serum drawn immediately
prior to surgery (n = 149 SCC cases and 290 controls)
[45]. We observed increased odds of SCC associated with
increasing JC antibody levels, which may reflect the detection of JC reactivation arising from immune dysregulation
associated with skin cancer. Therefore, our findings of an
association between JC serostatus and SCC could represent
the predisposing role of immunodeficiency, rather than
the virus itself. With limited statistical power, there was
weak evidence that the association we found between SCC
and JC seropositivity may be slightly stronger among those
with prolonged oral glucocorticoid use, raising the possibility of effect modification rather than confounding by
immunosuppression. However, further studies are needed.
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MCV, TSV, HPyV6, and HPyV7 show evidence of skin
tropism [36], yet we found no association with SCC risk.
We could not assay for the presence of PyV DNA within
SCC tumor tissues, which is a more direct indication of
a potential association between PyVs and SCC. In the
Florida study, MCV TAg DNA was isolated from ~40%
of SCC tumors from patients, but they did not find BK,
JC, KI, or WU TAg DNA sequences within SCC tumors
[44]. Other small studies have failed to detect DNA from
JC in skin swabs [80] or skin biopsies from normal skin
[81], common warts, Bowen’s disease [82], BCC [83],
SCC [81, 83], melanoma [81, 84], or cutaneous B-
cell
lymphomas [85]. However, JC TAg sequences were detected
in Kaposi’s sarcoma skin lesions, and has been amplified
from 16% of healthy skin tissues [86], suggesting that
these viruses can inhabit the skin even without being
skin tropic [36] or the skin acting as a suitable host for
viral propagation [87]. A potential etiologic role of JC
in the absence of JC DNA within tumors remains unexplained and warrants additional study.
All human PyVs discovered thus far encode proteins
that allow them to act as oncoviruses. Indeed, the virus’
name is derived from the Greek poly meaning ‘many’ and
oma referring to their induction of tumors in murine
models [88]. Truncating mutations in the large TAg of
integrated MCV are characteristic of MCC tumors, with
domains required for Rb-induced cell transformation preserved, while those for viral replication and p53 binding
[43] are eliminated resulting in no interaction with p53
[89], thereby enhancing the likelihood of cell survival.
Truncating mutations of the TAg have not been described
in other human PyVs. Consequent to its transforming
potential, the large TAg has been considered the main
oncoprotein in PyVs [36]. The small TAg and agnoprotein
expressed by some viruses also exhibit oncogenic properties
[36]. The late regions of BK and JC encode an agnoprotein
which exerts a tumorigenic effect through cell cycle dysregulation, interference with DNA repair processes, and
increased chromosome instability [90, 91]. Similar to SV40
[92], BK, JC, and MCV encode a miRNA that downregulates large TAg expression, which may allow the virus to
escape the immune system [93]. Thus, there is some evidence for a putative mechanistic role for PyVs in human
carcinogenesis, although further research is needed.
It has been theorized that PyVs may serve as cofactors
for oncoviruses by acting on common tumorigenic targets,
perturbing the cell cycle, assisting with immune evasion,
or transactivating the promoters of co-infecting viruses—
although evidence of such an interaction is lacking [29].
Interactions between PyVs and other viruses have been
documented, such as the in vitro cooperation between JC
and the HIV-1 regulatory protein, Tat, that enhances JC
transcription in glial cells [94, 95]. Additionally,
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interactive effects between a murine PyV strain with
Moloney murine leukemia virus have been shown to result
in stunted growth only in co-
infected animals, possibly
through a proinflammatory cytokine pathway [96]. In our
study, we were only able to assess concomitant seropositivity to β HPVs, and did not detect any consistent interactions with PyV types and SCC risk.

Strengths and limitations
A strength of our study was the large number of histologically confirmed cases of incident invasive SCC identified
through active population-based surveillance, along with
controls derived from the general US population. This
type of study design decreases the opportunity for selection bias, and is more generalizable than clinic-or hospital-
based case–control studies. Still, the possibility of selection
bias and residual confounding cannot be excluded, and
the generalizability to non-
white populations is limited
due to the study’s location in an almost exclusively white
US population. The use of multiplex serology to comprehensively measure a wide range of human PyVs was
an additional study strength. The GST capture of recombinantly expressed VP1 capsid proteins has been found
to be a reliable technique to assess PyV seroreactivity and
has been used as a marker of PyV infection in prior
studies [44, 58, 62]. Our blood samples were collected
following the skin cancer diagnosis, and thus PyV infection may have occurred during or following tumor development, and the influence of disease state on susceptibility
to PyV infection and immune response cannot be disentangled from these data. We are unable to assess temporality or reverse causality, so the direction of any observed
associations cannot be determined. PyV seropositivity does
not necessarily correspond to the presence of PyV DNA
in tumor tissues and seroreactivity is an indirect measure
of infection. However, MCV viral load and antibody titer
have been shown to have a strong positive monotonic
correlation [97], with higher MFI values corresponding
to MCV DNA-
positive SCC tumor tissues [44]. Lastly,
given the high seroprevalence of PyVs in the study population, power to detect differences in SCC risk for some
PyVs was limited.

Conclusions
In this population-based case–control study, we examined
the association between the first 10 discovered human
PyVs and incidence of SCC using multiplex serology. Our
findings, though limited, provide some support for the
possibility that specific PyV types may play a role in the
occurrence of SCC in the US population, but not PyV
seropositivity in general.
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Supporting Information
Additional supporting information may be found in the
online version of this article:
Table S1. Odds ratios (95% confidence intervals) for
cutaneous squamous cell carcinoma (SCC) by quartiles
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of polyomavirus (PyV) seroreactivity among 713 study
participants from the New Hampshire Skin Cancer Study.
Table S2. Odds ratios (95% confidence intervals) for
cutaneous squamous cell carcinoma (SCC) by seropositivity
for all cutaneous polyomaviruses (PyV), and by number
of cutaneous PyV types seropositive, among 713 study
participants from the New Hampshire Skin Cancer Study.
Figure S1. Spearman rank correlation coefficients, ρ, between
the median fluorescence intensity (MFI) values against each
human polyomavirus (PyV) VP1 or T antigen (TAg) among
460 controls from the New Hampshire Skin Cancer Study,
where *P<0.05, **P<0.01, ***P<0.001. Not all PyV TAgs
were assayed, and MCV large TAg was assayed using the
entire protein as well as with two fragments (exon 1 and
exon 2) of the full length large TAg. The red triangle
emphasizes the strong correlations between PyV TAgs.
Figure S2. Robustness of odds ratio (OR) estimates for
cutaneous squamous cell carcinoma (SCC) by seropositivity
for each polyomavirus (PyV) type among 713 study participants from the New Hampshire Skin Cancer Study,
following adjustment for age group and gender. The cut
points were varied from 50 to 450 median fluorescence
intensity (MFI) units (x axis), and the resulting ORs were
calculated using the new cutoffs (y axis). The red dots
show the ORs using the recommended cutoff of 250 MFI
units. The blue dots denote the cut points calculated using
a frequency distribution analysis described in van der
Meijden et al, 2013 (67). OR estimates for HPyV10 could
not be accurately computed due to the viruses’ high seroprevalence. The gray bands are the 95% confidence intervals
(CI) about each OR.
Figure S3. Plot of odds ratios (95% confidence intervals
as whiskers) for cutaneous squamous cell carcinoma (SCC)
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by seropositivity for each polyomavirus (PyV) type among
study participants from the New Hampshire Skin Cancer
Study, when excluding participants with a history of organ
transplantation (“organ”, n = 1 control and 6 cases),
restricting to participants with no previous skin cancers
(“NMSC”, n = 423 controls and 179 cases), and excluding participants with a concomitant basal cell carcinoma
(“BCC”, n = 22 cases), following adjustment for age
group and gender. “Main” refers to unstratified risk estimates presented in Figure 1. The dashed line represents
an OR=1.
Figure S4. Plot of odds ratios (95% confidence intervals
as whiskers) for cutaneous squamous cell carcinoma
(SCC) by seropositivity for each polyomavirus (PyV)
type among study participants from the New Hampshire
Skin Cancer Study, when stratified by oral glucocorticoid
use for 1 month or longer (“yes” refers to use (n = 39
controls and 33 cases) and “no” to nonuse (n = 415
controls and 211 cases); as people with a history of
glucocorticoid use may also have undergone organ transplantation, we restricted the analysis to those who were
not organ transplant recipients), β HPV seropositivity
(“≥2” (n = 125 controls and 82 cases) and “<2” (n = 335
controls and 171 cases) refers to number of β HPV
seropositive), and SCC location (“head” (n = 146 cases)
refers to SCC located on the head or neck, and “other”
(n = 97 cases) refers to SCC located on other body
parts), following adjustment for age group and gender.
“Main” refers to unstratified risk estimates presented in
Figure 1. OR and 95% CI were not computed for strata
in which all participants were seropositive for the PyV
of interest (represented by a solid vertical black line).
The dashed line represents an OR=1.
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